ADOI Monographs
7 May 2024
Vol. 16 No. s2 (2024): ADOI monograph - Cutaneous lymphomas
Systemic treatments with monoclonal antibodies in mycosis fungoides and Sézary syndrome
Publisher's note
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.
702
Views
538
Downloads
Authors
Mycosis fungoides (MF) and Sézary syndrome (SS) are the most prevalent non-Hodgkin lymphomas that comprise cutaneous T-cell lymphomas (CTCL), accounting for more than 70% of cases. Following the Tumor Lymph nodes Metastasis Blood system, disease staging is carried out, and within ten years, about thirty percent of patients in the early stages will have advanced disease. Plaques, folliculotropism, and age over 60 are risk factors for progression. A 5-year survival rate of less than 20% is associated with LCT in MF. Treatment requires an interdisciplinary approach; skindirected therapies are available for early stages of the disease, but there are no curative options for advanced stages of the disease other than allogeneic stem cell transplantation. Because of their severe symptoms and poor treatment efficacy, patients in advanced stages have a lower quality of life and a lower chance of survival. In patients with CD30-expressing CTCL, Brentuximab Vedotin has demonstrated better response rates and progression-free survival (PFS); in advanced SS, mogamulizumab has significantly increased PFS. These findings emphasize the need to standardize prognostic factors and improve CTCL treatment.
Altmetrics
Downloads
Download data is not yet available.
Citations
Willemze R, Cerroni L, Kempf W, et al. The 2018 update of the WHO-EORTC classification for primary cutaneous lymphomas. Blood 2019;133:1703-14. DOI: https://doi.org/10.1182/blood-2018-11-881268
Olsen EA, Whittaker S, Willemze R, et al. Primary cutaneous lymphoma: recommendations for clinical trial design and staging update from the ISCL, USCLC, and EORTC. Blood 2022;140:419-37. DOI: https://doi.org/10.1182/blood.2021012057
Scarisbrick JJ, Quaglino P, Prince HM, et al. The PROCLIPI international registry of early-stage mycosis fungoides identifies substantial diagnostic delay in most patients. Br J Dermatol 2019;181:350-7. DOI: https://doi.org/10.1111/bjd.17258
Ghazawi FM, Netchiporouk E, Rahme E, et al. Comprehensive analysis of cutaneous T-cell lymphoma (CTCL) incidence and mortality in Canada reveals changing trends and geographic clustering for this malignancy. Cancer 2017;123:3550-67. DOI: https://doi.org/10.1002/cncr.30758
Khodadoust MS, Mou E, Kim YH. Integrating novel agents into the treatment of advanced mycosis fungoides and Sezary syndrome. Blood 2023;141:695-703. DOI: https://doi.org/10.1182/blood.2020008241
Prince HM, Kim YH, Horwitz SM, et al. Brentuximab vedotin or physician’s choice in CD30-positive cutaneous T-cell lymphoma (ALCANZA): an international, open-label, randomised, phase 3, multicentre trial. Lancet 2017;390:555-66. DOI: https://doi.org/10.1016/S0140-6736(17)31266-7
Kim YH, Bagot M, Pinter-Brown L, et al. Mogamulizumab versus vorinostat in previously treated cutaneous T-cell lymphoma (MAVORIC): an international, open-label, randomised, controlled phase 3 trial. Lancet Oncol 2018;19:1192-204. DOI: https://doi.org/10.1016/S1470-2045(18)30379-6
Duvic M, Tetzlaff MT, Gangar P, et al. Results of a phase II trial of brentuximab vedotin for CD30+ cutaneous T-cell lymphoma and lymphomatoid papulosis. J Clin Oncol 2015;33:3759-65. DOI: https://doi.org/10.1200/JCO.2014.60.3787
Kim YH, Tavallaee M, Sundram U, et al. Phase II investigator-initiated study of brentuximab vedotin in mycosis fungoides and Sézary syndrome with variable CD30 expression level: a multi-institution collaborative project. J Clin Oncol 2015;33:3750-8. DOI: https://doi.org/10.1200/JCO.2014.60.3969
Barta SK, Liu N, DerSarkissian M, et al. Real-world treatment patterns and clinical outcomes with Brentuximab vedotin or other standard therapies in patients with previously treated cutaneous T-Cell lymphoma in the United States. Clin Lymphoma Myeloma Leuk 2023. Online ahead of print. DOI: https://doi.org/10.1016/j.clml.2023.10.001
Muniesa C, Gallardo F, García-Doval I, et al. Brentuximab vedotin in the treatment of cutaneous T-cell lymphomas: Data from the Spanish Primary Cutaneous Lymphoma Registry. J Eur Acad Dermatol Venereol 2023;37:57-64. DOI: https://doi.org/10.1111/jdv.18563
Papadavid E, Kapniari E, Pappa V, et al. Multicentric EORTC retrospective study shows efficacy of brentuximab vedotin in patients who have mycosis fungoides and Sézary syndrome with variable CD30 positivity. Br J Dermatol 2021;185:1035-44. DOI: https://doi.org/10.1111/bjd.20588
Ishii T, Ishida T, Utsunomiya A, et al. Defucosylated humanized anti-CCR4 monoclonal antibody KW-0761 as a novel immunotherapeutic agent for adult T-cell leukemia/lymphoma. Clin Cancer Res 2010;16:1520-31. DOI: https://doi.org/10.1158/1078-0432.CCR-09-2697
Cowan RA, Scarisbrick JJ, Zinzani PL, et al. Efficacy and safety of mogamulizumab by patient baseline blood tumour burden: a post hoc analysis of the MAVORIC trial. J Eur Acad Dermatol Venereol 2021;35:2225-38. DOI: https://doi.org/10.1111/jdv.17523
Horwitz S, Zinzani PL, Bagot M, et al. Lack of impact of type and extent of prior therapy on outcomes of mogamulizumab therapy in patients with cutaneous T cell lymphoma in the MAVORIC trial. Leuk Lymphoma 2021;62:3109-18. DOI: https://doi.org/10.1080/10428194.2021.1953007
Beygi S, Duran GE, Fernandez-Pol S, et al. Resistance to mogamulizumab is associated with loss of CCR4 in cutaneous T-cell lymphoma. Blood 2022;139:3732-6. DOI: https://doi.org/10.1182/blood.2021014468
Beylot-Barry M, Quereux G, Nardin C, et al. Effectiveness of mogamulizumab in patients with mycosis fungoides or Sézary syndrome: a multicentre, retrospective, real-world French study. J Eur Acad Dermatol Venereol 2023;37:1777-84. DOI: https://doi.org/10.1111/jdv.19134
Hirotsu KE, Neal TM, Khodadoust MS, et al. Clinical characterization of mogamulizumab-associated rash during treatment of mycosis fungoides or Sézary syndrome. JAMA Dermatol 2021;157:700-7. DOI: https://doi.org/10.1001/jamadermatol.2021.0877
Blanchard G, Guenova E. Mogamulizumab-associated rash (MAR) mars its efficacy in the treatment of cutaneous lymphoma. Br J Dermatol 2022;186:15-6. DOI: https://doi.org/10.1111/bjd.20821
How to Cite
Systemic treatments with monoclonal antibodies in mycosis fungoides and Sézary syndrome. (2024). Dermatology Reports, 16(s2). https://doi.org/10.4081/dr.2024.9970
Copyright (c) 2024 the Author(s)
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
